Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab-WIBP versus Humira in moderate to severe plaque psoriasis
CTR20202167Phase 3Active
- Sponsor
- Wuhan Institute of Biological Products
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of adalimumab in plaque psoriasis, sponsored by Wuhan Institute of Biological Products. Started Nov 2020; status: active.
02
Drugs
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20202167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202167.